옵션 체인은 다양한 행사가격과 만기일에 대한 Organon의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Organon에 대한 시장 심리를 평가합니다..

Organon (NYSE:OGN) 주식, 옵션 체인

Organon

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Organon & Co

Origin Protocol - United States Dollar

OROGEN ROYALTIES INC by Orogen Royalties Inc.

Orogen Royalties Inc

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

Wedbush analyst Seth Basham reiterates Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Neutral and maintains $215 price target.

News

Price Target

Reiteration

Analyst Ratings

Wedbush Reiterates Neutral on Dick's Sporting Goods, Maintains $215 Price Target

UBS analyst Graham Doyle downgrades Smith &amp; Nephew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) from Buy to Neutral.

Downgrades

UBS Downgrades Smith & Nephew to Neutral

Wedbush analyst Robert Driscoll reiterates Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) with a Outperform and maintains $8 price target.

HOWL

Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories xx Vs 5.737M Barrel Draw; 2.500M Barrel Draw Est.; 1.433M Barrel Draw Prior

EIA Weekly Distillates Stocks 1.559M Barrel Draw; 1.400M Barrel Draw Est.; 1.318M Barrel Draw Prior

Macro Notification

General

USA Crude Oil Inventories 1.448M Barrel Build Vs 2.100M Barrel Build Est. 3.614M Barrel Build Prior

Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) shares surged Wednesday after the company disclosed a significant deal with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44274834/visionary-ventures-into-the-new-energy-vehicle-battery-swap-field-in-hong-kong-providing-strong-as" rel="noreferrer noopener">PEGASUS International Group (Hong Kong)</a>.
Under the deal, Visionary will invest HK$420 million ($54 million) to establish 600 battery swap and charging stations across Hong Kong by 2029.
The plan includes constructing 10 stations in 2025, with the first new energy vehicle battery swap station set to launch in March 2025.
To facilitate the successful execution of this plan, the previously announced $1 billion financing agreement between Visionary and Qatar&#8217;s Alfardan Group has progressed into the formal loan process.
This milestone ensures financial backing for the investment, making the project feasible and actionable.
Visionary and PEGASUS International Group (Hong Kong) are leveraging their respective strengths to drive growth in Hong Kong&#8217;s new energy vehicle battery swap and charging market.
Visionary will contribute its expertise in equipment, technology, and financial operations, while PEGASUS will provide valuable site resources and other strategic advantages.
Together, they will oversee project operations, fostering a collaborative partnership that ensures mutual benefit and long-term success.
This strategic expansion is expected to enable Visionary to capture approximately 20% of the battery swap market share in&nbsp;Hong Kong.&nbsp;
Notably, the industry is poised for substantial growth with strong government support for new energy vehicle adoption and a plan to build 3,000 high-speed battery swaps and charging stations by 2030.
Earlier this month, Visionary secured a 12,000-vehicle order for Hong Kong&#8217;s taxi market, promoting<a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44193667/why-is-visionary-holdings-stock-surging-today" rel="noreferrer noopener"> green transportation with electric taxis</a>.
Price Action: GV shares are up 26.7% at $6.30 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44275297" target="_blank" rel="noreferrer noopener">Nokia Powers Canal+ Telecom&#8217;s Fiber Network Expansion In The Caribbean</a></li>
</ul>
Photo via Shutterstock.

Equities

Contracts

Small Cap

Movers

Why Is Visionary Holdings Stock Rocketing On Wednesday?

WIIM

ZIM Integrated Shipping shares are trading lower. The company reported Q4 financial results.

Lam Research's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NYSE">LRCX</a>) short percent of float has fallen 14.54% since its last report. The company recently reported that it has 24.86 million shares sold short, which is 1.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Lam Research Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741789828_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lam Research has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Lam Research's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Lam Research's peer group average for short interest as a percentage of float is 9.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

LRCX

Is the Market Bullish or Bearish on Lam Research?

Everest Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) short percent of float has fallen 3.88% since its last report. The company recently reported that it has 878 thousand shares sold short, which is 3.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Everest Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741789823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Everest Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Everest Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Everest Group's peer group average for short interest as a percentage of float is 2.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Everest Group's Recent Short Interest

Fortinet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NYSE">FTNT</a>) short percent of float has risen 32.24% since its last report. The company recently reported that it has 17.96 million shares sold short, which is 2.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Fortinet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741789818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fortinet has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fortinet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Fortinet's peer group average for short interest as a percentage of float is 5.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FTNT

What Does the Market Think About Fortinet?

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.4%. Currently, AECOM has a market capitalization of $12.67 billion. 
Buying $100 In ACM: If an investor had bought $100 of ACM stock 10 years ago, it would be worth $325.57 today based on a price of $96.20 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741789811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Wedbush analyst Yun Zhong reiterates Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) from Outperform to Outperform.

VYGR

Wedbush Reiterates Outperform on Voyager Therapeuticsto Outperform

Avidity Biosciences shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and anounced a $72 price target.

Wedbush analyst Laura Chico maintains Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) with a Outperform and lowers the price target from $4 to $3.

OVID

Wedbush Maintains Outperform on Ovid Therapeutics, Lowers Price Target to $3

Scotiabank analyst Nicholas Yulico maintains W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) with a Sector Perform and raises the price target from $59 to $63.

Scotiabank Maintains Sector Perform on W.P. Carey, Raises Price Target to $63

Wedbush analyst Laura Chico reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Outperform and maintains $36 price target.

DNTH

Wedbush Reiterates Outperform on Dianthus Therapeutics, Maintains $36 Price Target

PepsiCo shares are trading lower after Jefferies downgraded the stock  from buy to hold and lowered the price target from $171 to $170.

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) with a Outperform and raises the price target from $27 to $28.

ATXS

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $28

Scotiabank analyst Himanshu Gupta maintains Nexus Ind REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NXR#TSX">NXR</a>) with a Sector Outperform and lowers the price target from C$9 to C$8.5.

TSX:NXR

TSX:NXR/UN

Scotiabank Maintains Sector Outperform on Nexus Ind REIT, Lowers Price Target to C$8.5

Press Releases

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Reports Results for the Third Quarter Ended September 30, 2024

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

ROIV

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Organon

Organon (OGN) 옵션

Organon (NYSE:OGN) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌